Types of Cancer We Treat

Ovarian Cancer

Our gynecologic oncologists diagnose ovarian cancer and treat it using the latest surgical procedures, including minimally invasive, robotic-assisted, and fertility-sparing approaches and clinical trials.

Our gynecologic oncologists, genetic counselors, and fertility specialists offer services for women at an increased genetic risk of developing ovarian cancer. Our experts help you carefully consider whether screening or risk-reduction surgery is right for you.

We understand how important quick decisions are in treating ovarian cancer, so we generally see you within 48 hours of your appointment request. We complement cancer care with support services, including integrative health therapies, psychological support, genetic testing, and survivorship plans.

Meet Our Doctors
Dr. Douglas Levine
Our Approach to Ovarian Cancer Treatment Our Approach to Ovarian Cancer Treatment
Diagnosis
Ovarian Cancer Diagnosis
Surgery
Ovarian Cancer Surgery
Fertility-Sparing Procedures
Ovarian Cancer Fertility-Sparing Procedures
Chemotherapy & Targeted Drugs
Ovarian Cancer Chemotherapy and Targeted Drugs

Related News

What You Need to Know About Treating Ovarian Cancer
Read Story
Managing the Side Effects of Chemotherapy for Ovarian Cancer
Read Story
Using Biomarkers to Guide Ovarian Cancer Treatment Decisions
Read Story
Immunotherapy Unexpectedly Effective for Rare Ovarian Cancer
Read Story
A Better Understanding Emerges of Ovarian Cancer
Read Story
Study Suggests Most Ovarian Cancers Start in Fallopian Tubes
Read Story
Many Pelvic Tumors in Women Start in Fallopian Tubes
Read Story
Changes in Gene Contribute Independently to Cancer Risk
Read Story
Surgeon & Scientist Named Director of Gynecologic Oncology
Read Story
New Pathway for Stalling BRCA Tumor Growth Revealed
Read Story

Clinical Trials and Research Studies

Phase 1

A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Solid Tumors and Lymphomas

Learn More

Phase 3

The OVAL Study: A Randomized Controlled Double-Arm Open-Label Multi-Center Study of VB-111 Combined with Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Learn More

Phase 2

A Multicenter Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

Learn More

Phase 3

A RANDOMIZED DOUBLE-BLIND PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM- BASED THERAPY AS FIRST LINE TREATMENT OF STAGE III OR IV NON-MUCINOUS EPITHELIAL OVARIAN CANCER

Learn More
View All Related Clinical Trials (8)